Back to Search
Start Over
The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges
- Source :
- Journal of Infection and Public Health, Vol 15, Iss 2, Pp 228-240 (2022), Journal of Infection and Public Health
- Publication Year :
- 2021
-
Abstract
- Graphical abstract<br />Background The SARS-CoV-2 coronavirus epidemic is hastening the discovery of the most efficient vaccines. The development of cost-effective vaccines seems to be the only solution to terminate this Pandemic. However, the vaccines’ effectiveness has been questioned due to recurrent mutations in the SARS-CoV-2 genome. Most of the mutations are associated with the spike protein, a vital target for several marketed vaccines. Many Countries were highly affected by the 2nd wave of the SARS-CoV-2, like the UK, India, Brazil, France. Experts are also alarming the further COVID-19 wave with the emergence of Omicron, which is highly affecting the South African populations. This review encompasses the detailed description of all vaccine candidates and COVID-19 mutants that will add value to design further studies to combat the COVID-19 Pandemic. Methods The information was generated using various search engines like google scholar, PubMed, clinicaltrial.gov.in, WHO database, ScienceDirect, and news portals by using keywords SARS-CoV-2 Mutants, COVID-19 Vaccines, Efficacy of SARS-CoV-2 Vaccines, COVID-19 waves. Results This review has highlighted the evolution of SARS-CoV2 variants and the vaccine efficacy. Currently, various vaccine candidates are also undergoing several phases of development. Their efficacy still needs to check for newly emerged variants. We have focused on the evolution, multiple mutants, waves of the SARS-CoV-2, and different marketed vaccines undergoing various clinical trials and the design of the trials to determine vaccine efficacy. Conclusion Various mutants of SARS-CoV-2 arrived, mainly concerned with the spike protein, a key component to design the vaccine candidates. Various vaccines are undergoing clinical trial and show impressive results, but their efficacy still needs to be checked in different SARS-CoV-2 mutants. We discussed all mutants of SARS-CoV-2 and the vaccine's efficacy against them. The safety concern of these vaccines is also discussed. It is important to understand how coronavirus gets mutated to design better new vaccines, providing long-term protection and neutralizing broad mutant variants. A proper study approach also needs to be considered while designing the vaccine efficacy trials, which further improved the study outcomes. Taking preventive measures to protect from the virus is also equally important, like vaccine development.
- Subjects :
- COVID-19 Vaccines
CNBG, China National Biotec Group
Vaccine efficacy
VOI, Variant of Interest
RVZV, recombinant varicella-zoster vaccine
Review
Infectious and parasitic diseases
RC109-216
GISAID, Global Initiative on Sharing All Influenza Data
PHE, Public Health Emergency
WIBP, Wuhan Institute of Biological Products
Clinical trials
Humans
SAE, Serious adverse events
NTD, N-terminal domain
ADDE, Antibody dependent disease enhancement
CDC, Centre for Disease Control and Prevention
CMV, Cytomegalovirus
WGS, whole-genome sequencing
Pandemics
ComputingMethodologies_COMPUTERGRAPHICS
HPVV, human papillomavirus vaccine
R.C.T., Randomised Clinical Trials
Vaccines
COVE, Coronavirus Efficacy
SARS-CoV-2
EUAL, Emergency Use Assessment and Listing
Public Health, Environmental and Occupational Health
VOC, Variant of Concern
RBD, receptor-binding domain
COVID-19
VOHC, Variant of High Consequence
General Medicine
Variant strains
VE, Vaccine effectiveness
BIBP, Beijing Institute of Biological Products
NERVTAG, New and Emerging Respiratory Virus Threats Advisory Group
Infectious Diseases
NIAID, National Institute of Allergy and Infectious Diseases
HBV, hepatitis B virus vaccine
Mutation
AAs, Amino acids
Public aspects of medicine
RA1-1270
SIADP, Sharing All Influenza Data platform
Mutations
ACE2, Angiotensin-converting enzyme receptor 2
Subjects
Details
- ISSN :
- 1876035X
- Volume :
- 15
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Journal of infection and public health
- Accession number :
- edsair.doi.dedup.....827203f5324d600cf0e5f929eaa39255